Pharmacology of bronchodilators.
In the UK, diseases that cause airflow obstruction are common. About 5.1 million people receive treatment for asthma and about 600,000 people are diagnosed as having chronic obstructive pulmonary disease (COPD), although this is likely to be an underestimate (British Thoracic Society, 2001).
National Respiratory Training Centre, Warwick.
Rachel
R
Booker
D000280:Administration, Inhalation; D058666:Adrenergic beta-2 Receptor Agonists; D001341:Autonomic Nervous System / Q000187:drug effects / Q000502:physiology; D001993:Bronchodilator Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D004347:Drug Interactions; D016903:Drug Monitoring / Q000379:methods; D004359:Drug Therapy, Combination; D004638:Emergency Treatment; D006801:Humans; D008168:Lung / Q000187:drug effects; D055370:Lung Injury; D009330:Nebulizers and Vaporizers; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D012129:Respiratory Function Tests; D012307:Risk Factors; D013806:Theophylline / Q000494:pharmacology / Q000627:therapeutic use; D006113:United Kingdom / Q000453:epidemiology
D058666:Adrenergic beta-2 Receptor Agonists; D001993:Bronchodilator Agents; D018680:Cholinergic Antagonists; D010726:Phosphodiesterase Inhibitors; D013806:Theophylline